Heartland Advisors’s Viridian Therapeutics VRDN Stock Holding History

Heartland Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-511	Closed	-$252K	–	243
2015 Q2	$252K	Sell	511 -378	-43%	-$153K	0.01%	231
2015 Q1	$430K	Buy	889 +37	+4%	+$21.4K	0.01%	227
2014 Q4	$487K	Buy	852 +52	+7%	+$37.4K	0.01%	241
2014 Q3	$810K	Buy	+800	New	+$944K	0.02%	238

Other funds holding VRDN

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

ICAS

Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Heartland Advisors's VRDN Position: Q3 2015 in Review

Heartland Advisors sold out of Viridian Therapeutics (VRDN) in Q3 2015, closing a stake of 511 shares — an estimated $252K sold.

Heartland Advisors first reported a position in VRDN in Q3 2014 and held it in 4 quarters. The position peaked at $810K in Q3 2014. 10 funds tracked by Wall St. Rank hold VRDN as of Q3 2015.

Heartland Advisors reported no remaining Viridian Therapeutics position as of Q3 2015 after selling out during the quarter.
Heartland Advisors sold 511 Viridian Therapeutics shares in Q3 2015, an estimated $252K.
Heartland Advisors first reported a position in Viridian Therapeutics in Q3 2014 and held it in 4 quarters.
Heartland Advisors's Viridian Therapeutics position peaked at $810K in Q3 2014.
10 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2015.

Based on Heartland Advisors's 13F filing for Q3 2015, filed 4 Nov 2015.